FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
JUNE 2018

POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
OPHTHALMOLOGY
PAPER-IV
TIME: 3 HOURS OPH/J/18/26/IV
MAX. MARKS: 100
IMPORTANT INSTRUCTIONS
This question paper consists of 10 questions divided into Part "A" and part each part
containing 5 questions.
Answers to questions of part A and part B are to be strictly attempted in separate answer sheet(s)
and the main supplementary answer sheet(s) used for each part must be tagged separately.
Answers to question(s) of Part A attempted in answer sheet(s) of part B or Vice versa shall not be
evaluated.
Answer sheets of Part A and Part B are not to be tagged together.
Part A and Part B should be mentioned only on the covering page of the respective answer sheets.
Attempt all questions in order.
Each question carries 10 marks.
Read the question carefully and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
PART A
1. Role of Botulinum toxin in strabismus.
What is Faden operation?
6+4
2. Recent advances in the endothelial keratoplasty. 10
3. Newer advances in refractive surgery. 10
4. Principles of MRI and its role in practice of Ophthalmology. 4 6
5. "Progressive Glasses" design.
When to use it and its advantages over conventional
glasses?
6+4
6. Intravitreal implants and indications for their use.
What are their possible side effects?
7+3
7. Management of recurrent viral keratitis.
Discuss two newer imaging modalities of anterior segment of
eye.
5+5
8. Management of unilateral cataract in a 2-year-old child. 10
9. Management of unilateral 5-day old chemical burn.
Newer concepts in the management of ocular burns.
5+5
10. Newer advances in the management of 2 DD unilateral
retinoblastoma in the presenting eye and when presenting in
the fellow eye in bilateral retinoblastoma.
5+5